Media

Positive results show that C21 can become an important complement to COVID-19 vaccines

BONESUPPORT moves to Mid Cap

Spruce Biosciences Added to Russell 2000®, 3000® and Microcap® Indexes

Vicore Pharma announces Last Patient Last Visit in the mechanistic phase II study with C21 in systemic sclerosis

Fusion Pharmaceuticals Initiates Multi-Dose Portion Of Phase 1 Trial Of FPI-1434 In Patients With Advanced Solid Tumors

GenSight Biologics Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine

Full data set of Oncopeptides phase 2 HORIZON study in multiple myeloma published in the Journal of Clinical Oncology

Vicore Pharma reports positive top line data from the ATTRACT clinical study in patients with COVID-19

Oncopeptides will host a webcast on Wednesday, December 9[th] at 14:00 (CET) to provide an update regarding data presented at the ASH annual meeting

Orexo Enters Exclusive License and Supply Agreement with Accord Healthcare for ZUBSOLV[® ]in Europe